Circulating microRNAs can predict chemotherapy-induced toxicities in patients being treated for primary breast cancer

Breast Cancer Res Treat. 2023 Nov;202(1):73-81. doi: 10.1007/s10549-023-07033-8. Epub 2023 Aug 4.

Abstract

Purpose: Prescribing NAC for breast cancer is a pragmatic treatment strategy for several reasons; however, certain patients suffer chemotherapy-induced toxicities. Unfortunately, identifying patients at risk of toxicity often proves challenging. MiRNAs are small non-coding RNA molecules which modulate genetic expression. The aim of this study was to determine whether circulating miRNAs are sensitive biomarkers that can identify the patients likely to suffer treatment-related toxicities to neoadjuvant chemotherapy (NAC) for primary breast cancer.

Methods: This secondary exploratory from the prospective, multicentre translational research trial (CTRIAL ICORG10/11-NCT01722851) recruited 101 patients treated with NAC for breast cancer, from eight treatment sites across Ireland. A predetermined five miRNAs panel was quantified using RQ-PCR from patient bloods at diagnosis. MiRNA expression was correlated with chemotherapy-induced toxicities. Regression analyses was performed using SPSS v26.0.

Results: One hundred and one patients with median age of 55 years were recruited (range: 25-76). The mean tumour size was 36 mm and 60.4% had nodal involvement (n = 61) Overall, 33.7% of patients developed peripheral neuropathies (n = 34), 28.7% developed neutropenia (n = 29), and 5.9% developed anaemia (n = 6). Reduced miR-195 predicted patients likely to develop neutropenia (P = 0.048), while increased miR-10b predicted those likely to develop anaemia (P = 0.049). Increased miR-145 predicted those experiencing nausea and vomiting (P = 0.019), while decreased miR-21 predicted the development of mucositis (P = 0.008).

Conclusion: This is the first study which illustrates the value of measuring circulatory miRNA to predict patient-specific toxicities to NAC. These results support the ideology that circulatory miRNAs are biomarkers with utility in predicting chemotherapy toxicity as well as treatment response.

Keywords: Breast cancer; Chemotherapies; MiRNA; Personalised medicine; Precision oncology; Treatment toxicities.

MeSH terms

  • Antineoplastic Agents* / therapeutic use
  • Biomarkers, Tumor / genetics
  • Breast Neoplasms* / drug therapy
  • Breast Neoplasms* / genetics
  • Breast Neoplasms* / pathology
  • Circulating MicroRNA* / genetics
  • Circulating MicroRNA* / therapeutic use
  • Female
  • Gene Expression Regulation, Neoplastic
  • Humans
  • MicroRNAs* / genetics
  • Middle Aged
  • Neutropenia* / drug therapy
  • Peripheral Nervous System Diseases* / drug therapy
  • Prospective Studies

Substances

  • Circulating MicroRNA
  • MicroRNAs
  • Antineoplastic Agents
  • Biomarkers, Tumor
  • MIRN145 microRNA, human